Georgia's Online Cancer Information Center

Find A Treatment Site

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

Nancy N. and J.C. Lewis Cancer & Research Pavilion (LCRP) at St. Joseph's/Candler
NCI Community Cancer Centers Program (NCCCP)
Savannah, Georgia

The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) is a network of hospital cancer centers that serve as a community-based platform to support basic, clinical, and population-based research initiatives across the cancer care continuum—from prevention, screening, diagnosis, treatment, and survivorship through end-of-life care. One of the goals of the NCCCP is to increase access to clinical trials in a community setting. Through a strategic partnership between the NCI and participating hospitals, the NCCCP is a hospital-based cancer center network designed to support cancer research, and enhance access to and increase quality of care at community hospitals so more patients benefit from the latest research.

The Nancy N. and J.C. Lewis Cancer & Research Pavilion (LCRP) was one of the first of ten health systems selected by the NCCCP in 2007 to participate in what was originally a pilot program. It has since grown to a full-fledged program with 30 locations. As a National Cancer Institute NCCCP site, clinical research is one of the top goals of the LCRP. Every month the LCRP initiates several new clinical trials and anticipates having trials to offer patients with virtually every type and stage of cancer. Scientific breakthroughs lead to positive changes in the fight against cancer, and these trials will assist the LCRP in its dedication to deliver the best level of patient care in their own community.

www.sjchs.org
www.cancerpavilion.com

Treatment Sites in Georgia

Clinical Trials in Georgia

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Cancer Type: Melanoma

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type: Ovarian Cancer

Abemaciclib and Letrozole to Treat Endometrial Cancer
Cancer Type: Unknown Primary, Uterine Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Cancer Type: Prostate Cancer , Unknown Primary

AVB-S6-500 (Batiraxcept)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary

CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Cancer Type: Prostate Cancer , Unknown Primary

Circulating Tumor DNA Testing in Predicting Treatment for Patients with Stage IIA Colon Cancer After Surgery, COBRA Trial
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Collection of Research Data and Samples from Patients Treated with Immunotherapy to Study Its Side Effects
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients with Pancreatic Cancer That Has Spread
Cancer Type: Pancreatic Cancer, Unknown Primary

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type: Lung Cancer

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type: Breast Cancer

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Effect of Treatment on Work Experience in Patients with Stage I-III Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol
Cancer Type: Solid Tumor

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses
Cancer Type: Hematopoietic Malignancies

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Immunotherapy with Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab with Cabozantinib for Patients with Advanced Kidney Cancer, The PDIGREE Study
Cancer Type: Bone Tumor

Improving Patient-Centered Communication in Breast Cancer through Patient and Provider Interventions, SHADES Study
Cancer Type: Breast Cancer, Unknown Primary

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery
Cancer Type: Breast Cancer, Unknown Primary

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Solid Tumor

Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Cancer Type: Esophogeal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer

Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary

Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
Cancer Type: Solid Tumor

Radiation Therapy with or without Olaparib in Treating Patients with Inflammatory Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

Regional Radiation Therapy with or without Whole Breast Irradiation in Treating Patients with Estrogen Receptor Positive, HER2 Negative Low Risk Breast Cancer Who Have Undergone Breast Conserving Surgery or Mastectomy
Cancer Type: Breast Cancer

Serum Tumor Marker Directed Disease Monitoring in Monitoring Patients with Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Cancer Type: Breast Cancer

Smoke Free Support Study 2.0
Cancer Type: Hematopoietic Malignancies, Solid Tumor, Unknown Primary

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery, STAMP Study
Cancer Type: Neuroendocrine Tumor, Skin Cancer (Non-Melanoma), Unknown Primary

Testing Ramipril to Prevent Memory Loss in People with Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases.
Cancer Type: Brain Tumor, Breast Cancer

Testing the Ability to Decrease Chemotherapy in Patients with HER2-Positive Breast Cancer Who Have No Remaining Cancer at Surgery after Limited Pre-operative Chemotherapy and HER2-Targeted Therapy
Cancer Type: Breast Cancer

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) during Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Cancer Type: Cervical Cancer, Gynecologic Cancers

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients with Chronic Lymphocytic Leukemia
Cancer Type: Leukemia

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Cancer Type: Lung Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
Cancer Type: Lung Cancer

Testing the Addition of an Antibody to Standard Chemoradiation followed by the Antibody for One Year to Standard Chemoradiation followed by One Year of the Antibody in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Cancer Type: Multiple Myeloma

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type: Lung Cancer

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients with Early Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Cancer Type: Unknown Primary, Uterine Cancer

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Cancer Type: Unknown Primary, Uterine Cancer

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory Endometrial Cancer following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Cancer Type: Uterine Cancer

Testing the Effects of MK-3475 (Pembrolizumab) with or without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older with Advanced Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] plus Pembrolizumab) against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Testing what Happens when an Immunotherapy Drug (Avelumab) Is Added to a Usual Drug Treatment (Cetuximab) Compared to Avelumab by Itself in the Treatment of Advanced Squamous Cell Carcinoma of the Skin (cSCC)
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

Testing Whether Avoiding the Hippocampus During Whole-Brain Radiation Therapy Prevents Cognitive Side Effects in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients with Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Cancer Type: Melanoma

Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, SOLARIS Trial
Cancer Type: Colon/Rectal Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.